The purpose of the present protocol is to evaluate the response rate to treatment of these symptomatic benign nodules with radiofrequency as an alternative to surgical treatment. This thyroid nodules ablation with radiofrequency will be directed by a single percutaneous procedure guided by ultrasound. The procedure includes an ultrasound with percutaneously radiofrequency ablation of benign thyroid nodule. Clinical and ultrasonographic monitoring will last a year with consultations at 2 weeks (consultation only), 3 months, 6 months and 1 year (consultation, ultrasound TSH). The success of this procedure will be controlled with 3 successive ultrasounds the following year. The expected results are a decrease in the size of the nodule by at least 50% and a reduction in the functional and aesthetic discomfort, with less frequent complication than what is expected with surgery. The present study also intends to determine the medico economic impact of this technique compared to surgery.
Thyroid benign nodules represent a major public health problem because they are very common (subclinical nodules were found in half of woman beyond 60 years). The main risk factors include age, female gender, parity, smoking and family history of thyroid nodules or thyroiditis. The assessment is based on biology, ultrasound and fine needle aspiration and intends to determine the benign nature (95%) or cancer (5%) of the nodules and if they are functional or not (toxic nodule). Most benign nodules are asymptomatic but some of them because of their size and location can cause a functional disorder (compression or swallowing disorder) or aesthetic and psychological resounding.In current practice, these nodules are sometimes treated with surgery that impact on patient quality of life (need to take L-Thyroxine, difficulties related to the possible occurrence of complications like hypoparathyroidism or laryngeal paralysis) and socio-economic constraints especially when complications occur. To limit the number of unnecessary and potentially risky surgeries, patients should therefore be well selected. If surgery is the preferred treatment of thyroid cancer, alternative techniques like radiofrequency seem interesting for benign nodules.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
CHU Toulouse, Hôpital Larrey
Toulouse, France
Procedure response rate
First estimate of the procedure response rate (patient with complete procedure in percentage)
Time frame: 6 months
Change in nodular volume
compared to the volume measured at inclusion. This reduction will be estimated in absolute value and in relative value (percentage reduction for a given subject)
Time frame: at 6 and 12 months
volume change of nodules by at least 50 percent, at 6 months
Percentage of patients with a volume decrease of at least 50 percent, 6 months after the procedure. Patients for which the procedure could not be fully performed will be counted among patients who have not had a reduction of at least 50 percent
Time frame: at 6 months
volume change of nodules by at least 50 percent, at 12 months
Percentage of patients with a volume decrease of at least 50 percent, 12 months after the procedure. Patients for which the procedure could not be fully performed will be counted among patients who have not had a reduction of at least 50 percent
Time frame: at 12 months
complete disappearance of symptoms
The symptoms will be evaluated by a visual analogue scale of 0 to 10 as proposed by the Korean consensus. The symptoms assessed will be: cervical pain, dysphagia, foreign body sensation, discomfort, coughing.
Time frame: at 12 months
aesthetic change
This improvement will be evaluated with a 4-level scale (no clinically detectable nodule 0, palpable nodule 1, visible nodule on swallowing 2, spontaneously visible nodule 3) as proposed by the Korean consensus. The improvement will be defined by the transition to the lower category.
Time frame: at 3, 6 and 12 months
one or more complications
In particular, the following will be investigated: signs of cutaneous involvement such as burns, hematoma and intra-nodular bleeding, recurrent paralysis, superinfections, tracheal or esophageal wounds.
Time frame: at 6 and 12 months
Assessment of pain during the procedure with visual analogue scale
Evaluation of the pain during the procedure using a visual analogue scale from 0 to 10 established at the end of the procedure
Time frame: between Day 1 and Day 15
patients requiring L-thyroxine replacement therapy
Percentage of patients requiring L-thyroxine replacement therapy
Time frame: at 6 and 12 months
Economic evaluation from the point of view of the hospital
evaluation, from the point of view of the hospital, of the production cost of the new technique
Time frame: Between Day 1 and 12 months
patients who have used analgesics
Percentage of patients who have used analgesics during and after the procedure
Time frame: between Day 1 and Day 15
Economic evaluation from the point of view of the health insurance
Evaluation, from the point of view of health insurance, of the cost of the care of patients who benefited from the new technique
Time frame: Between Day 1 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.